ProKidney Corp. (PROK) - Total Liabilities
Based on the latest financial reports, ProKidney Corp. (PROK) has total liabilities worth $34.78 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ProKidney Corp. - Total Liabilities Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s total liabilities have evolved over time, based on quarterly financial data. See PROK working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
ProKidney Corp. Competitors by Total Liabilities
The table below lists competitors of ProKidney Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rane Holdings Limited
NSE:RANEHOLDIN
|
India | Rs24.18 Billion |
|
Magnora ASA
OL:MGN
|
Norway | Nkr78.70 Million |
|
Orrön Energy AB (publ)
ST:ORRON
|
Sweden | Skr152.48 Million |
|
King Core Electronics Inc
TW:6155
|
Taiwan | NT$649.91 Million |
|
Springsnow Food Group Co Ltd
SHG:605567
|
China | CN¥1.09 Billion |
|
Qinhuangdao Port Co Ltd
F:QHD
|
Germany | €6.38 Billion |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
India | Rs10.95 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down ProKidney Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PROK stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProKidney Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProKidney Corp. (2019–2025)
The table below shows the annual total liabilities of ProKidney Corp. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.78 Million | -11.80% |
| 2024-12-31 | $39.44 Million | +34.98% |
| 2023-12-31 | $29.22 Million | +123.76% |
| 2022-12-31 | $13.06 Million | -2.42% |
| 2021-12-31 | $13.38 Million | +95.74% |
| 2020-12-31 | $6.84 Million | +83.57% |
| 2019-12-31 | $3.72 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more